Researchers in Japan have found the Lambda COVID-19 variant exhibits higher infectivity and immune resistance to vaccines than the version of the virus that first emerged in Wuhan, China. A recently published preprint of a Japanese study, which has yet to be peer-reviewed, suggests said the Lambda variant, first detected in Peru, is able to resist vaccine-induced neutralizing antibodies that can fight off the CCP (Chinese Communist Party) virus. In laboratory experiments, the researchers found that three mutations in the variant’s spike protein help it bypass the antibodies, while two further mutations help make it more infectious. The Lambda variant, also known as C.37, is believed to have first emerged in Peru in August last year, but has only been recognized as a potential global threat in recent months, with the World Health Organization (WHO) declaring it a variant of interest on June 17 after it appeared in several countries …